Clinical trials: Segment Elevation Myocardial Infarction (STEMI)
ST-segment Elevation Myocardial Infarction
Optimal Coronary Flow After PCI for Myocardial Infarction - a Pilot Study
In this study the investigators test the hypothesis that alteplase given intra coronary after PCI reduce infarct size in patients with ST-elevation myocardial infarction(STEMI) and impaired microvascular function defined as a…
- Trial name
- OPTIMAL (NCT02894138)
- Testing
- alteplase
- Where
- Sweden
- Volunteers
- 80 people
- Sponsor
- Vastra Gotaland Region
Acute Coronary Syndrome, ST Segment Elevation Myocardial Infarction
MAGnesium-based Bioresorbable Scaffold in ST Segment Elevation Myocardial Infarction
This is a prospective, randomized, active control, single-blind, non-inferiority, multicenter clinical trial. 148 subjects will be registered at up to 10 Spanish sites. Subjects will be followed for 5 years.
- Conditions
- Acute Coronary Syndrome, ST Segment Elevation Myocardial Infarction, Stent
- Trial name
- MAGSTEMI (NCT03234348)
- Testing
- Percutaneous coronary intervention
- Where
- 11 sites in Spain
- Volunteers
- 151 people
- Sponsor
- Hospital Clinic of Barcelona
Cardiogenic Shock
CorVad Myocardial Infarction Complicated with Cardiogenic Shock Trial
Cardiogenic shock a serious complication of a heart attack (myocardial infarction). Despite evaluation of several new treatments during the last decade, the mortality in patients with cardiogenic shock still exceeds 50%.
- Trial name
- Corvad AMICS (NCT06886113)
- Testing
- Conventional circulatory support, CorVad
- Where
- China
- Volunteers
- 269 people, healthy volunteers welcome
- Sponsor
- Shenzhen Core Medical Technology CO.,LTD.
ST Segment Elevation Myocardial Infarction (STEMI), Allogeneic Mesenchymal Bone Marrow Cells
A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With ST Segment Elevation Myocardial Infarction (STEMI)
The purpose of this study is to assess the safety and tolerability of human allogeneic mesenchymal bone marrow cells (aMBMC) administered intravenously to subjects with ST Segment Elevation Myocardial Infarction (STEMI).
- Trial name
- NCT01770613
- Testing
- Stem cells
- Where
- 2 sites in United States
- Sponsor
- Stemedica Cell Technologies, Inc.
STEMI - ST Elevation Myocardial Infarction
ST-segment Elevation Not Associated With Acute Cardiac Necrosis (LESTONNAC)
Patients with chest pain and persistent ST segment elevation (STE) may not have acute coronary occlusions or serum troponin curves suggestive of acute necrosis.
- Trial name
- LESTONNAC (NCT05689970)
- Testing
- AI platform to detect ST elevation in ECG
- Where
- 7 sites in Spain
- Volunteers
- 420 people
- Sponsor
- Idoven 1903 S.L.
Myocardial Infarction, Coronary Artery Disease
Coronary Artery Healing and Bioresorbable Scaffold
To compare coronary healing after optical coherence tomography guided versus conventionally angiography guided percutaneous coronary intervention with the Magmaris bioresorbable scaffold.
- Trial name
- HONEST (NCT03016624)
- Testing
- OCT guided PCI, Angiography guided PCI
- Where
- Denmark
- Volunteers
- 75 people
- Sponsor
- Odense University Hospital
STEMI - ST Elevation Myocardial Infarction
Century Clot-Guided Prophylactic Rivaroxaban for Post STEMI Complicating Left Ventricular Thrombus
To manage the ST-segment elevation myocardial infarction (STEMI) caused by plaque rupture, triggers platelet activation/aggregation and thrombin generation, requires dual (platelet and coagulation) pathway inhibition.
- Trial name
- NCT06013020
- Testing
- NOAC+DAPT, DAPT
- Where
- China
- Volunteers
- 374 people
- Sponsor
- Zunyi Medical College
ST-segment Elevation Myocardial Infarction
Association Between Plasma Melatonin and No-reflow
ST-segment elevation myocardial infarction (STEMI) is an acute manifestation of coronary heart disease, remaining a frequent cause of death.
- Trial name
- NCT03306303
- Volunteers
- 1,700 people
- Sponsor
- Chinese PLA General Hospital
Acute Cardiovascular Disease, ST-segment Elevation Myocardial Infarction (STEMI)
MAchine Learning to Boost the Early Diagnosis of Acute Cardiovascular Conditions
The research project aims to develop clinical decision support tools integrating established diagnostic variables and machine learning (ML) models for rapid diagnosis of acute life-threatening cardiovascular conditions in…
- Conditions
- Acute Cardiovascular Disease, ST-segment Elevation Myocardial Infarction (STEMI), NSTEMI - Non-ST Segment Elevation MI
- Trial name
- MALBEC (NCT06927791)
- Testing
- Machine learning based development of a diagnostic tool for acute cardiovascular disease
- Where
- Switzerland
- Volunteers
- 200,000 people
- Sponsor
- University Hospital, Basel, Switzerland
STEMI
CMR Repeatability in STEMI
The investigators propose to conduct a study to measure the reproducibility of CMR parameters that have been used to predict outcome following PPCI: infarct size, left ventricular volumes, myocardial salvage, microvascular…
- Trial name
- NCT01468662
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- University of Bristol
STEMI - ST Elevation Myocardial Infarction (MI)
Assessment of Prognosis and Myocardial Reperfusion in Patients with ST-segment-elevation Myocardial Infarction (STEMI) According to Coronary Atherosclerotic Burden.
In the current literature, it has been widely demonstrated that the extend of coronary atherosclerotic burden is associated with adverse long-term outcomes.
- Trial name
- NCT06876974
- Volunteers
- 2,200 people
- Sponsor
- Central Hospital, Nancy, France
Myocardial Infarction
MCC-135 as Adjunct Therapy to Primary Percutaneous Coronary Intervention in ST-Segment Elevation Acute Myocardial Infarction Patients
This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial. The primary objectives of this study are to examine the safety, tolerability, and efficacy of intravenous MCC-135 in limiting final infarct…
- Trial name
- NCT00078013
- Testing
- MCC-135
- Where
- United States
- Volunteers
- 414 people
- Sponsor
- Tanabe Pharma Corporation
ST-segment Elevation Myocardial Infarction (STEMI)
PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction
The aim of this study is to evaluate the safety of prasugrel monotherapy without aspirin versus 12-month dual antiplatelet therapy (DAPT) in patients with STEMI using platinum-chrome everolimus-eluting stent (PtCr-EES: SYNERGYTM).
- Trial name
- PREMIUM (NCT05709626)
- Testing
- No aspirin (Prasugurel monotherapy), 12-month DAPT
- Where
- Japan
- Volunteers
- 2,258 people
- Sponsor
- Kindai University
Myocardial Infarct, Remodeling, Left Ventricle
Heart Attack Blood Oxygen Therapy Trial
'Heart attack', known as acute ST-segment elevation myocardial infarction, is a leading cause of heart failure and death. A lack of blood and oxygen damages the heart muscle potentially causing heart failure and premature death.
- Trial name
- SSO2 Radial MI (NCT06662890)
- Testing
- Supersaturated oxygen
- Where
- United Kingdom
- Volunteers
- 56 people
- Sponsor
- NHS National Waiting Times Centre Board
ST-segment Elevation Myocardial Infarction
Efficacy and Safety Study of Deferred Stenting in Patients With STEMI
It is known that no reflow phenomenon by microvascular obstruction after revascularization in STEMI increase infarct size, cardiac remodeling, and a risk of late mortality.
- Trial name
- INNOVATION (NCT02324348)
- Testing
- Deferred coronary stenting, Immediate coronary stenting
- Where
- South Korea
- Volunteers
- 114 people
- Sponsor
- Korea University Anam Hospital
ST-segment Elevation Myocardial Infarction (STEMI), Percutaneous Coronary Intervention
Cardioprotective Effect of Dexmedetomidine in Patients With ST-segment Elevation Myocardial Infarction
This is a double-blind, multicenter, randomized, placebo-controlled clinical trial. It is planned to enroll patients admitted with anterior ST-segment elevation myocardial infarction (STEMI) within 6h of symptom onset and undergo…
- Conditions
- ST-segment Elevation Myocardial Infarction (STEMI), Percutaneous Coronary Intervention, Cardioprotection
- Trial name
- COOPERATION (NCT04912518)
- Testing
- Dexmedetomidine (DEX)
- Where
- 9 sites in China
- Volunteers
- 250 people
- Sponsor
- Harbin Medical University
Acute Coronary Syndromes, Chest Pain
AI-ECG Detection of Occlusion Myocardial Infarction at Emergency Department Triage (TRIACS)
Chest pain is among the most common reasons people attend an emergency department, and the electrocardiogram (ECG) recorded at triage is the first test used to decide who needs urgent treatment for a blocked coronary artery.
- Conditions
- Acute Coronary Syndromes, Chest Pain, Myocardial Infarction (MI), NSTEMI - Non-ST Segment Elevation MI
- Trial name
- TRIACS-MB (NCT07882849)
- Where
- Slovenia
- Volunteers
- 1,000 people
- Sponsor
- University Medical Centre Maribor
ST Elevation Myocardial Infarction
Reduced Stent Strategy Versus Conventional Percutaneous Coronary Revascularization in Patients Presenting With STEMI
The objective is to compare a reduced stent strategy based on drug-coated balloon (DCB) percutaneous coronary intervention (PCI) with conventional drug-eluting stent (DES) coronary revascularization in patients presenting with…
- Trial name
- COPERNICAN (NCT06353594)
- Testing
- Primary PCI
- Where
- 23 sites in Spain
- Volunteers
- 1,272 people
- Sponsor
- Hospital Universitario La Fe
ST Elevation Myocardial Infarction
The Predictive Value of eGFR for Adverse Cardiovascular Events in Patients With STEMI
Estimated glomerular filtration rate(eGFR) is significantly reduced in patients with ST-segment elevation myocardial infarction (STEMI).
- Trial name
- NCT03984071
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Dongying Zhang
Myocardial Infarction
AMI-DC in Patients With Anterior Wall Myocardial Infarction
The purpose of this trial is to assess the safety of AMI-DC treatment. The participants who voluntarily sign the consent form will be screened according to the inclusion/exclusion criteria then allocated either to the…
- Trial name
- AMI-DC (NCT05554484)
- Testing
- Autologous peripheral blood-derived tolerogenic dendritic cells
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- The Catholic University of Korea